

Accelerating the Path to Patients: AI-Enabled Protocol Optimization in an Era of Complex Clinical Trials

Andrew Kuhlman, MS, Clinical Research Specialist, Clinical Research Methodology

Michael F Murphy, MD, PhD, Chief Scientific and Medical Officer

Clinical trial protocols are increasingly complex documents that define how new therapies are tested, but they are often inefficient and error prone. Studies indicate that over 40% of trials have protocols which are less than optimal across a number of dimensions,¹ leading to frequent amendments and delays in drug development. In fact, 76% of trials now undergo at least one protocol amendment, commonly related to unanticipated operational encumbrances.² These issues may contribute to low overall success rates (<12% of drug candidates pass trials) and lengthy development cycles.³ Artificial intelligence (AI) has emerged as a promising aid to streamline protocol development and amplify the contributions of “human-in-the-loop” oversight.

AI can assist across nearly all protocol sections in varying degrees, contingent upon the innovation of the test product and stage of development. It excels at data-driven drafting, consistency checking, and optimizing design elements based on precedent, which is invaluable for sections like design and schedule.

Crucially, AI is not replacing human expertise but augmenting it, particularly in the era of advanced therapeutics and highly nuanced patient phenotypes. Clinicians, statisticians, and trial managers must inform the AI algorithm, verify its outputs, and provide the context and judgment that algorithms lack. Sections that involve ethical judgments, innovative design choices, or nuanced criteria require substantial oversight by subject matter experts relevant to the discipline. AI thus is best for repetitive and data-intensive tasks, while human experts guide the study’s scientific narrative, safeguard patient interests, and review all AI-generated results.

Not all protocol sections benefit equally from AI assistance – some can be largely automated or optimized by AI, while others demand significant human judgment. Below is a section-by-section analysis:

Protocol Elements & the Utility/Limitations of Current AI Systems

Protocol Element	Background & Scientific Rationale	Study Design & Trial Objectives	Objectives & Endpoints	Eligibility Criteria (Inclusion/Exclusion)	Study Treatments & Procedures	Statistical Analysis Plan	Regulatory & Ethical Compliance	Investigational Product & Administrative Sections
AI Contribution	Literature synthesis, prior trial analysis, aggregating regulatory precedents	Analyze historical trial designs, recommend control arms and design frameworks	Identify commonly used endpoints, align endpoints with regulatory guidance, and detect inconsistencies	Evaluate real-world patient availability, model recruitment feasibility, and identify overly restrictive criteria	Generate schedules of assessments, align procedures with endpoints, and identify patient burden	Perform power simulations and draft standardized statistical language	Populate regulatory language, ensure compliance with protocol templates, and detect missing sections	Extract product information from reports, auto-generate protocol administrative sections, and maintain consistency
Human Contribution	Verify scientific accuracy, add expert interpretation, and align narrative with regulatory strategy	Final study design decisions, ethical and regulatory feasibility, and strategic positioning of therapy	Choose clinically meaningful endpoints, evaluate patient relevance, and select novel biomarkers or endpoints	Ensure safety of enrolled patients, balance generalizability and risk, and manage ethical and regulatory considerations	Confirm operational feasibility, determine necessary procedures, and adapt schedules to real-world constraints	Choose statistical models, ensure regulatory compliance, and define analysis strategies and assumptions	Tailor consent procedures, ensure regulatory acceptability, and manage safety oversight plans	Verify accuracy of product data, approve final protocol documentation, and ensure confidentiality and compliance

AI’s utility in protocol development spans all phases and therapeutic areas, although the magnitude of contributions varies by phase of development. Earlier-phase protocols offer greater flexibility and innovation for AI applications, whereas later-phase protocols demand rigor and predictability, where AI is used primarily for optimization rather than creation of innovative trial design.⁴ In complex, high-failure-rate areas (i.e., oncology, CNS, or rare diseases), AI can assist with informing trial design intricacies and significantly amplify the subject matter expertise which is ubiquitously required.⁵ In more established areas (i.e., later phase cardiovascular or metabolic indications), AI can serve as a powerful optimizer and risk reducer, ensuring large trials are as efficient and targeted as possible, particularly if they are informed by precedent studies.⁶

Current AI Tools & Platforms for Protocol Development

Multiple AI-powered platforms are already accessible, or piloted, in the pharmaceutical industry to support protocol development. These range from document drafting assistants to advanced analytics suites. Note that many of these systems are still undergoing validation and require human oversight. Below are some notable, real-world AI tools and their listed capabilities:

Representative AI Tools & Platforms for Protocol Development

Protocol-Related Task	AI-Assisted Protocol Authoring ^{7,8}	Protocol Design Optimization Platforms ⁹⁻¹¹	Patient Recruitment & Feasibility Tools ^{12,13}	Document Compliance & Quality Control ^{7,9,14-16}	Integrated AI Platforms (End-to-End) ^{17,18}
Representative AI Tools Available	<ul style="list-style-type: none"> Clinion eProtocol GPT-based protocol drafting tools 	<ul style="list-style-type: none"> Trials.ai (ZS Smart Study) Phesi Trial Accelerator Medidata AI 	<ul style="list-style-type: none"> TrialGPT BEKHealth Dyania Health Carebox 	<ul style="list-style-type: none"> Clinion eProtocol PWS AI Compliance tool Bridges-2 TrialAssure Trials.ai 	<ul style="list-style-type: none"> Unlearn TrialPioneer PWC “Smarter Trials” framework
Product Features	<ul style="list-style-type: none"> Auto-generate large portions of clinical trial protocols from a short study synopsis Produce protocols aligned with ICH M11 or TransCelerate templates Accelerate document drafting and reduce manual writing effort Reduce protocol development time by weeks and improve document consistency and compliance 	<ul style="list-style-type: none"> Analyze large databases of historical trials and patient data Recommend optimal trial design elements such as endpoints, eligibility criteria, and study schedules Predict trial feasibility and risk before study launch Optimize objectives, endpoints, eligibility criteria, and schedule of assessments Predict impact of design decisions on time, cost, risk, and patient burden Identify protocol features associated with amendments or recruitment problems 	<ul style="list-style-type: none"> Convert protocol eligibility criteria into searchable databases Identify eligible patients using electronic health records (EHRs) Automated eligibility matching and rapid site feasibility assessments Significantly reduce screening time in recruitment 	<ul style="list-style-type: none"> Detect inconsistencies or missing sections in protocols Ensure compliance with regulatory templates (e.g., ICH M11) Provide version control and audit trails for regulatory submissions Automated quality checks across protocol sections Cross-validation between endpoints, procedures, and data collection plans Audit-ready traceability of document edits 	<ul style="list-style-type: none"> Provide unified platform integrating literature review, design optimization, and trial simulation Enable scenario testing for different protocol designs Use digital twin models and predictive analytics to guide trial planning Literature mining tools to gather evidence for protocol rationale Simulation tools to test different trial designs Predictive models to estimate trial success probability

Thus, currently available AI tools for protocol development focus on two broad areas: (1) content generation and compliance, and (2) data-driven design optimization. Substantial improvements, including faster drafting times, fewer protocol amendments, and more predictable enrollment have been reported.³ More than half of AI startups in the clinical trial space are targeting patient recruitment and protocol optimization, reflecting the industry’s pain points.¹³

Emerging AI Capabilities in Protocol Development

Looking forward, a new wave of AI capabilities promises to further transform how protocols are developed, pushing beyond today's mostly assistive tools toward more autonomous and intelligent systems. Some emerging AI capabilities and trends include:

Scientific Rationale	Study Design & Trial Objectives	Objectives & Endpoints	Eligibility Criteria (Inclusion/Exclusion)	Study Treatments & Procedures	Statistical Analysis Plan	Regulatory & Ethical Compliance
Summary	Emerging LLMs may generate complete protocol drafts, not just individual sections.	Next-generation AI systems ("agentic AI") may orchestrate multiple tasks autonomously, such as literature review, design simulation, and document drafting.	AI-generated digital patient models may soon simulate trial outcomes before studies begin.	AI may soon enable analysis of complex data streams such as wearables, imaging, and real-time patient monitoring.	AI may allow protocols to dynamically adjust based on patient characteristics, including AI-guided patient stratification, adaptive treatment allocation, and personalized trial pathways.	Regulatory agencies and industry groups are beginning to collaborate on AI frameworks for trial design, including transparency, validation, and mitigation of bias.

The next generation of AI in protocol development is poised to go beyond assistance to partnership, or even autonomy, in some areas. We will see AI not only writing and optimizing protocols at the outset but also being actively involved throughout the trial: simulating patient outcomes, triggering adaptations, and analyzing real-world data to refine ongoing studies.

An important emerging development in protocol design is the implementation of the International Council for Harmonisation (ICH) M11 guideline, which introduces a protocol template and technical specification to improve harmonization between sponsors, CROs, and regulators across different regions. The use of structured data as foreseen in the technical specification also promotes interoperability between digital systems, enabling the direct flow of protocol data into systems such as the Interactive Response Technology or Electronic Clinical Outcome Assessments. By shifting protocols from static documents to structured, reusable data, ICH M11 may significantly expand the utility of AI in protocol development through automated data extraction, consistency checking, and cross-platform communication throughout the clinical trial lifecycle.^{20,21}

Overall, the integration of AI into clinical protocol development marks a paradigm shift towards more efficient, intelligent, and adaptive clinical trials. By leveraging AI's strengths and remaining mindful of its limits, the pharmaceutical research community is poised to design trials that not only ask the right questions but answer them in the most efficient and patient-conscious way possible.

References

1. Fogel DB. Factors Associated with Clinical Trials That Fail and Opportunities for Improving the Likelihood of Success: A Review. *Contemp Clin Trials Commun.* 2018 Aug 7;11:156-164. PMID: 30112460. PMCID: PMC6092479. doi: 10.1016/j.conctc.2018.08.001.
2. Getz K, Smith Z, Botto E, Murphy E, Dauchy A. New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance. *Ther Innov Regul Sci.* 2024 May;58(3):539-548. Epub 2024 Mar 4. PMID: 38438658. doi: 10.1007/s43441-024-00622-9.
3. Olawade DB, Fidelis SC, Marinze S, Egbon E, Osunmakinde A, Osborne A. Artificial Intelligence in Clinical Trials: A Comprehensive Review of Opportunities, Challenges, and Future Directions. *Int J Med Inform.* 2026 Feb;206:106141. Epub 2025 Oct 8. PMID: 41075423. doi: 10.1016/j.ijmedinf.2025.106141.
4. Askin S, Burkhalter D, Calado C, El Dakrouni S. Artificial Intelligence Applied to Clinical Trials: Opportunities and Challenges. *Health Technol (Berl).* 2023;13(2):203-213. Epub 2023 Feb 28. PMID: 36923325; PMCID: PMC9974218. doi: 10.1007/s12553-023-00738-2.
5. Kolla L, Gruber FK, Khalid O, Hill C, Parikh RB. The Case for AI-Driven Cancer Clinical Trials - The Efficacy Arm In Silico. *Biochim Biophys Acta Rev Cancer.* 2021 Aug;1876(1):188572. Epub 2021 May 31. PMID: 34082064; PMCID: PMC8922906. doi: 10.1016/j.bbcan.2021.188572.
6. Teodoro D, Naderi N, Yazdani A, Zhang B, Bornet A. A Scoping Review of Artificial Intelligence Applications in Clinical Trial Risk Assessment. *NPJ Digit Med.* 2025 Jul 30;8(1):486. PMID: 40731070; PMCID: PMC12307910. doi: 10.1038/s41746-025-01886-7.

References

7. Clinion eProtocol Automation. <https://www.clinion.com/protocol-automation/>.
8. Building blocks: The Ultimate Guide to AI in Clinical Trials. Medable. Guide. Sep 30, 2025. <https://www.medable.com/knowledge-center/guides-building-blocks-the-ultimate-guide-to-ai-in-clinical-trials>.
9. Trials.ai. <https://trials.ai/index.html>.
10. Phesi Protocol Design and Optimization. <https://www.phesi.com/services/protocol-design-optimization/>.
11. Medidata. <https://www.medidata.com/en/clinical-trial-products/medidata-ai/>.
12. Jin Q, Wang Z, Floudas CS, Chen F, Gong C, Bracken-Clarke D, Xue E, Yang Y, Sun J, Lu Z. Matching Patients to Clinical Trials with Large Language Models. Nat Comms. 18 Nov 2024;15(9074 [2024]). PMID: 39557832. PMCID: PMC11574183. doi: 10.1038/s41467-024-53081-z.
13. How AI Is Transforming Clinical Trials. American Hospital Association. Insights. 2026. <https://www.aha.org/aha-center-health-innovation-market-scan/2025-10-21-how-ai-transforming-clinical-trials>.
14. AI Compliance Tool. PwC Czech Republic. 2026. <https://www.pwc.com/cz/en/sluzby/umela-intelligence-ai/ai-act/ai-compliance-tool.html>.
15. Chiacchia K. AI Helps Scientists Correct Mistakes in Medical Studies. Bridges-2, Science Highlights. 2 Oct 2025. <https://www.psc.edu/correcting-medical-studies/>.
16. TrialAssure. <https://trialassure.com/>.
17. Unlearn. <https://www.unlearn.ai/>.
18. Streamline Your Protocol Design for Operational Feasibility with Our Intelligent Clinical Trials Solution. PwC Czech Republic. <https://www.pwc.com/us/en/technology/alliances/amazon-web-services/healthcare-intelligent-automation-platform/intelligent-clinical-trial.html>.
19. Picket J, de Langsdorff V. The AI-enabled medical writer: A new era for regulatory writing. Medical Writing. 2025 Sep 1;34(3). doi: 10.56012/rjum8758
20. Georgieff T. Navigating Toward a Digital Clinical Trial Protocol. Applied Clinical Trials. 2023 Dec 1;32(12). <https://www.appliedclinicaltrialsonline.com/view/navigating-toward-a-digital-clinical-trial-protocol>.